Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% Debt-to-Equity is 0.37 as of Dec. 2025, which is 1133% above its 10-year median of 0.03. The stock has 8 warning signs investors should review. Among 557 Healthcare Providers & Services companies, Resonance Health ranks better than 52.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Resonance Health's Debt-to-Equity or its related term are showing as below:
ASX:RHT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.41
Current: 0.37
During the past 13 years, the highest Debt-to-Equity Ratio of Resonance Health was 0.41. The lowest was 0.01. And the median was 0.03.
ASX:RHT's Debt-to-Equity is ranked better than 52.06% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs ASX:RHT: 0.37
Resonance Health (ASX:RHT) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Resonance Health Debt-to-Equity Related Terms
Resonance Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Resonance Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: Debt-to-Equity Comparison
For the Health Information Services subindustry, Resonance Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Resonance Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Debt-to-Equity of 0.37 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Resonance Health and its competitors. This is 1133% above median its historical median of 0.03. Over the past decade, Resonance Health's Debt-to-Equity has ranged from 0.01 to 0.41. According to the industry distribution chart, Resonance Health ranks #267 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 47.9%.
Is Resonance Health's Debt-to-Equity too high?
Resonance Health's current Debt-to-Equity of 0.37 is 1133% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.41. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Resonance Health's value of 0.37 is 9.8% below this industry median. Based on the distribution chart, Resonance Health ranks #267 out of 557 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #267 out of 557 companies for Debt-to-Equity. This puts Resonance Health in the upper half of its industry. The industry median Debt-to-Equity is 0.41. Resonance Health's value of 0.37 is 9.8% below this benchmark. Historically, Resonance Health's own Debt-to-Equity has ranged from 0.01 to 0.41 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.41, Resonance Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Debt-to-Equity of 0.37 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Debt-to-Equity is 0.37, which is 1133% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current Debt-to-Equity is 0.37, which is 1133% above median its 10-year median of 0.03 and 9.8% below the Healthcare Providers & Services industry median of 0.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Debt-to-Equity is 0.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
